Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 4/2014

01-04-2014 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Does Disruption of Circadian Rhythms Contribute to Beta-Cell Failure in Type 2 Diabetes?

Authors: Kuntol Rakshit, Anthony P. Thomas, Aleksey V. Matveyenko

Published in: Current Diabetes Reports | Issue 4/2014

Login to get access

Abstract

Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by the loss of beta-cell secretory function and mass. The pathophysiology of beta-cell failure in T2DM involves a complex interaction between genetic susceptibilities and environmental risk factors. One environmental condition that is gaining greater appreciation as a risk factor for T2DM is the disruption of circadian rhythms (eg, shift-work and sleep loss). In recent years, circadian disruption has become increasingly prevalent in modern societies and consistently shown to augment T2DM susceptibility (partly mediated through its effects on pancreatic beta-cells). Since beta-cell failure is essential for development of T2DM, we will review current work from epidemiologic, clinical, and animal studies designed to gain insights into the molecular and physiological mechanisms underlying the predisposition to beta-cell failure associated with circadian disruption. Elucidating the role of circadian clocks in regulating beta-cell health will add to our understanding of T2DM pathophysiology and may contribute to the development of novel therapeutic and preventative approaches.
Literature
1.
DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96:2354–66.PubMedCrossRef
2.
Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976;42:222–9.PubMedCrossRef
3.
Seltzer HS, Allen EW, Herron Jr AL, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323–35.PubMedCentralPubMedCrossRef
4.
Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199–207.PubMedCrossRef
5.
Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74:1318–28.PubMedCentralPubMedCrossRef
6.
Porksen N, Hollingdal M, Juhl C, et al. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes. 2002;51 Suppl 1:S245–54.PubMedCrossRef
7.
Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855–61.PubMedCrossRef
8.
Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia. 2008;51:1100–10.PubMedCrossRef
9.
Meier JJ, Bonadonna RC. Role of reduced beta-cell mass versus impaired beta-cell function in the pathogenesis of type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S113–9.PubMedCrossRef
10.
Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.PubMedCrossRef
11.
Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10 Suppl 4:32–42.PubMedCrossRef
12.
Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45:85–96.PubMedCrossRef
13.
Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300–8.PubMedCrossRef
14.
Yoneda S, Uno S, Iwahashi H, et al. Predominance of beta-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab. 2013;98:2053–61.PubMedCrossRef
15.
Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89:5535–41.PubMedCrossRef
16.
Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–60.PubMedCentralPubMedCrossRef
17.
Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279:42351–4.PubMedCrossRef
18.
Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339–42.PubMed
19.
20.
Shu L, Sauter NS, Schulthess FT, et al. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes. 2008;57:645–53.PubMedCrossRef
21.
Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity. J Physiol. 2007;583:9–24.PubMedCentralPubMedCrossRef
22.
Schuit F, De Vos A, Farfari S, et al. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in beta cells. J Biol Chem. 1997;272:18572–9.PubMedCrossRef
23.
Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes. 1998;47:307–15.PubMedCrossRef
24.
Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990;39:647–52.PubMedCrossRef
25.
Ishihara H, Wang H, Drewes LR, et al. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. J Clin Invest. 1999;104:1621–9.PubMedCentralPubMedCrossRef
26.
Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev. 2005;85:1303–42.PubMedCrossRef
27.
Andersson SA, Olsson AH, Esguerra JL, et al. Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes. Mol Cell Endocrinol. 2012;364:36–45.PubMedCrossRef
28.
Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54:727–35.PubMedCrossRef
29.
MacDonald MJ, Longacre MJ, Langberg EC, et al. Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetes. Diabetologia. 2009;52:1087–91.PubMedCentralPubMedCrossRef
30.
Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. Nature. 2001;414:807–12.PubMedCrossRef
31.
Rosengren AH, Braun M, Mahdi T, et al. Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to type 2 diabetes. Diabetes. 2012;61:1726–33.PubMedCentralPubMedCrossRef
32.
Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest. 2013. doi:10.​1172/​JCI65390.
33.
Silva CM, Sato S, Margolis RN. No time to lose: workshop on circadian rhythms and metabolic disease. Genes Dev. 2010;24:1456–64.
34.
35.
36.
37.
Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science. 2002;295:1070–3.PubMedCrossRef
38.
Hattar S, Liao HW, Takao M, et al. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science. 2002;295:1065–70.PubMedCentralPubMedCrossRef
39.
Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci. 2001;2:521–6.PubMedCrossRef
40.•
Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010;466:627–31. First demonstration that targeted disruption of beta-cell molecular clock results in beta-cell failure and T2DM. The study was also the first to show that (1) pancreatic islets express self-sustained oscillations of clock genes, (2) disruption of the beta-cell circadian clock leads to hyperglycemia and overt glucose-intolerance, and (3) genetic disruption of the beta-cell circadian clock leads to impaired GSIS both in vitro and in vivo.PubMedCentralPubMedCrossRef
41.
Saini C, Suter DM, Liani A, et al. The mammalian circadian timing system: synchronization of peripheral clocks. Cold Spring Harb Symp Quant Biol. 2011;76:39–47.
42.
Takahashi JS, Hong HK, Ko CH, et al. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008;9:764–75.PubMedCentralPubMedCrossRef
43.
Gekakis N, Staknis D, Nguyen HB, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998;280:1564–9.PubMedCrossRef
44.
45.
Preitner N, Damiola F, Lopez-Molina L, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–60.PubMedCrossRef
46.
Guillaumond F, Dardente H, Giguere V, et al. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythm. 2005;20:391–403.CrossRef
47.
48.
Wyse CA, Selman C, Page MM, et al. Circadian desynchrony and metabolic dysfunction: did light pollution make us fat? Med Hypotheses. 2011;77:1139–44.PubMedCrossRef
49.
Beihl DA, Liese AD, Haffner SM. Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol. 2009;19:351–7.PubMedCrossRef
50.
US Congress OTA. Biological rythms: implications for the worker, OTA-BA-463. Washington DC: US Government Printing Office; 1991.
51.
Basner M, Fomberstein KM, Razavi FM, et al. American time use survey: sleep time and its relationship to waking activities. Sleep. 2007;30:1085–95.PubMedCentralPubMed
52.
Rutter J, Reick M, McKnight SL. Metabolism and the control of circadian rhythms. Annu Rev Biochem. 2002;71:307–31.PubMedCrossRef
53.
Kroenke CH, Spiegelman D, Manson J, et al. Work characteristics and incidence of type 2 diabetes in women. Am J Epidemiol. 2007;165:175–83.PubMedCrossRef
54.
Mikuni E, Ohoshi T, Hayashi K, et al. Glucose intolerance in an employed population. Tohoku J Exp Med. 1983;141(Suppl):251–6.PubMedCrossRef
55.•
Pan A, Schernhammer ES, Sun Q, et al. Rotating night shift work and risk of type 2 diabetes: 2 prospective cohort studies in women. PLoS Med. 2011;8:e1001141. The largest and most extensive prospective cohort study to date with ~20-year follow-up, found an increased risk of T2DM following chronic exposure to rotating shift work in women.PubMedCentralPubMedCrossRef
56.
Suwazono Y, Dochi M, Oishi M, et al. Shiftwork and impaired glucose metabolism: a 14-year cohort study on 7104 male workers. Chronobiol Int. 2009;26:926–41.PubMedCrossRef
57.
Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. Diabetes Care. 2005;28:2762–7.PubMedCrossRef
58.
Meisinger C, Heier M, Loewel H. Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population. Diabetologia. 2005;48:235–41.PubMedCrossRef
59.
Nilsson PM, Roost M, Engstrom G, et al. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004;27:2464–9.PubMedCrossRef
60.
Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006;29:657–61.PubMedCrossRef
61.•
Buxton OM, Cain SW, O'Connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med. 2012;4:129ra143. The first clear demonstration that exposure to circadian misalignment (with concurrent sleep restriction) for 3 weeks in otherwise healthy humans results in loss of appropriate beta-cell function.CrossRef
62.
63.
Qin LQ, Li J, Wang Y, et al. The effects of nocturnal life on endocrine circadian patterns in healthy adults. Life Sci. 2003;73:2467–75.PubMedCrossRef
64.•
Scheer FA, Hilton MF, Mantzoros CS, et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106:4453–8. Study reports that 10 days circadian misalignment caused the subjects to exhibit postprandial hyperglycemia and glucose intolerance, with a subset of individuals (~40 %) notably exhibiting glucose intolerance values classified as “prediabetic” according to the current diagnostic criteria.PubMedCentralPubMedCrossRef
65.
Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354:1435–9.PubMedCrossRef
66.
Gonnissen HK, Rutters F, Mazuy C, et al. Effect of a phase advance and phase delay of the 24-hour cycle on energy metabolism, appetite, and related hormones. Am J Clin Nutr. 2012;96:689–97.PubMedCrossRef
67.
Boden G, Ruiz J, Urbain JL, et al. Evidence for a circadian rhythm of insulin secretion. Am J Physiol. 1996;271:E246–52.PubMed
68.
Freinkel N, Mager M, Vinnick L. Cyclicity in the interrelationships between plasma insulin and glucose during starvation in normal young men. J Lab Clin Med. 1968;71:171–8.PubMed
69.
70.
Spiegel K, Knutson K, Leproult R, et al. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol. 2005;99:2008–19.PubMedCrossRef
71.
Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–16.PubMedCentralPubMedCrossRef
72.
Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41:82–8.PubMedCentralPubMedCrossRef
73.
74.
Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94.PubMedCrossRef
75.
Gale JE, Cox HI, Qian J, et al. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythm. 2011;26:423–33.CrossRef
76.
77.
78.•
Qian J, Block GD, Colwell CS, et al. Consequences of exposure to light at night on the pancreatic islet circadian clock and function in rats. Diabetes. 2013;62:3469–78. This study first demonstrated that circadian misalignment induced by 10 weeks exposure to constant light significantly alters the islet circadian clock function through impairment in the amplitude, phase, and inter-islet synchrony of clock gene oscillations.PubMedCrossRef
79.
Sadacca LA, Lamia KA, de Lemos AS, et al. An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. Diabetologia. 2011;54:120–4.PubMedCentralPubMedCrossRef
80.
81.
Vieira E, Marroqui L, Batista TM, et al. The clock gene Rev-erbalpha regulates pancreatic beta-cell function: modulation by leptin and high-fat diet. Endocrinology. 2012;153:592–601.PubMedCrossRef
82.•
Lee J, Moulik M, Fang Z, et al. Bmal1 and beta-cell clock are required for adaptation to circadian disruption, and their loss of function leads to oxidative stress-induced beta-cell failure in mice. Mol Cell Biol. 2013;33:2327–38. This work was the first to report that beta-cell failure consequent to beta-cell clock disruption is attributed to reduced antioxidant gene expression, mitochondrial dysfunction, and oxidative stress-induced mitochondrial uncoupling.PubMedCentralPubMedCrossRef
83.
Pi J, Collins S. Reactive oxygen species and uncoupling protein 2 in pancreatic beta-cell function. Diabetes Obes Metab. 2010;12 Suppl 2:141–8.PubMedCrossRef
84.
Wilking M, Ndiaye M, Mukhtar H, et al. Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal. 2013;19:192–208.PubMedCrossRef
85.
Kondratov RV, Kondratova AA, Gorbacheva VY, et al. Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev. 2006;20:1868–73.PubMedCentralPubMedCrossRef
Metadata
Title
Does Disruption of Circadian Rhythms Contribute to Beta-Cell Failure in Type 2 Diabetes?
Authors
Kuntol Rakshit
Anthony P. Thomas
Aleksey V. Matveyenko
Publication date
01-04-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 4/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0474-4

Other articles of this Issue 4/2014

Current Diabetes Reports 4/2014 Go to the issue

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Sulfonylureas: A New Look at Old Therapy

Health Care Delivery Systems in Diabetes (D Wexler, Section Editor)

Rational Use of Electronic Health Records for Diabetes Population Management

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Alzheimer’s Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Systematic Reviews to Ascertain the Safety of Diabetes Medications

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Nutrigenetics: Bridging Two Worlds to Understand Type 2 Diabetes

Obesity (J McCaffery, Section Editor)

Behavior Modification Techniques Used to Prevent Gestational Diabetes: A Systematic Review of the Literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits